Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene

British Journal of Haematology

Volumn 165, Issue 5, 2014, Pages 618-628

  Ommen, Hans B ^a   Hokland, Peter ^a   Haferlach, Torsten ^b   Abildgaard, Lotte ^a   Alpermann, Tamara ^b   Haferlach, Claudia ^b   Kern, Wolfgang ^b   Schnittger, Susanne ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

Acute myeloid leukaemia; Minimal residual disease; MLL; Relapse kinetics

Indexed keywords

CD135 ANTIGEN; MIXED LINEAGE LEUKEMIA PROTEIN; TRANSCRIPTION FACTOR RUNX1; DNA; MLL PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BIOASSAY; BLOOD SAMPLING; CANCER GROWTH; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE MARKER; GENE DUPLICATION; GENE LOCATION; GENE MUTATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MLL GENE; MOLECULAR PATHOLOGY; MOLECULAR STABILITY; PARTIAL TANDEM DUPLICATION; PRIORITY JOURNAL; RUNX1 GENE; SENSITIVITY ANALYSIS; SOMATIC MUTATION; CHROMOSOME ABERRATION; CLINICAL TRIAL; GENE TRANSLOCATION; GENETICS; LEUKEMIA, MYELOID, ACUTE; MULTICENTER STUDY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES; PROGNOSIS; RECURRENT DISEASE; TANDEM REPEAT; TUMOR GENE;

CHROMOSOME ABERRATIONS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GENE DUPLICATION; GENES, NEOPLASM; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASM, RESIDUAL; PROGNOSIS; RECURRENCE; TANDEM REPEAT SEQUENCES; TRANSLOCATION, GENETIC;

EID: 84900514839     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12792     Document Type: Article

References (48)

1. Abdelhamid, E., Preudhomme, C., Helevaut, N., Nibourel, O., Gardin, C., Rousselot, P., Castaigne, S., Gruson, B., Berthon, C., Soua, Z. & Renneville, A. (2012) Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia. Leukemia Research, 36, 316-323.
2. Abildgaard, L., Ommen, H.B., Lausen, B., Hasle, H. & Nyvold, C.G. (2013) A novel RT-qPCR assay for quantification of the MLL-MLLT3 fusion transcript in acute myeloid leukaemia. European Journal of Haematology, 91, 394-398.
3. Bacher, U., Haferlach, T., Schoch, C., Kern, W. & Schnittger, S. (2006) Implications of NRAS mutations in AML: a study of 2502 patients. Blood, 107, 3847-3853.
4. Bacher, U., Haferlach, C., Kern, W., Haferlach, T. & Schnittger, S. (2008) Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients. Blood, 111, 2527-2537.
5. Caldas, C., So, C.W., MacGregor, A., Ford, A.M., McDonald, B., Chan, L.C. & Wiedemann, L.M. (1998) Exon scrambling of MLL transcripts occur commonly and mimic partial genomic duplication of the gene. Gene, 208, 167-176.
6. Candoni, A., Tiribelli, M., Toffoletti, E., Cilloni, D., Chiarvesio, A., Michelutti, A., Simeone, E., Pipan, C., Saglio, G. & Fanin, R. (2009) Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. European Journal of Haematology, 82, 61-68.
7. Cheson, B.D., Bennett, J.M., Kopecky, K.J., Buchner, T., Willman, C.L., Estey, E.H., Schiffer, C.A., Doehner, H., Tallman, M.S., Lister, T.A., Lo-Coco, F., Willemze, R., Biondi, A., Hiddemann, W., Larson, R.A., Lowenberg, B., Sanz, M.A., Head, D.R., Ohno, R., Bloomfield, C.D. & International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. (2003) Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 21, 4642-4649.
8. Chou, W.C., Tang, J.L., Wu, S.J., Tsay, W., Yao, M., Huang, S.Y., Huang, K.C., Chen, C.Y., Huang, C.F. & Tien, H.F. (2007) Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia, 21, 998-1004.
9. Cilloni, D., Messa, F., Arruga, F., Defilippi, I., Gottardi, E., Fava, M., Carturan, S., Catalano, R., Bracco, E., Messa, E., Nicoli, P., Diverio, D., Sanz, M.A., Martinelli, G., Lo-Coco, F. & Saglio, G. (2008) Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica, 93, 921-924.
10. Cilloni, D., Renneville, A., Hermitte, F., Hills, R.K., Daly, S., Jovanovic, J.V., Gottardi, E., Fava, M., Schnittger, S., Weiss, T., Izzo, B., Nomdedeu, J., van der Heijden, A., van der Reijden, B.A., Jansen, J.H., van der Velden, V.H., Ommen, H., Preudhomme, C., Saglio, G. & Grimwade, D. (2009) Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a european LeukemiaNet study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 27, 5195-5201.
11. Corbacioglu, A., Scholl, C., Schlenk, R.F., Eiwen, K., Du, J., Bullinger, L., Frohling, S., Reimer, P., Rummel, M., Derigs, H.G., Nachbaur, D., Krauter, J., Ganser, A., Dohner, H. & Dohner, K. (2010) Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28, 3724-3729.
12. Fasan, A., Haferlach, C., Alpermann, T., Jeromin, S., Grossmann, V., Eder, C., Weissmann, S., Dicker, F., Kohlmann, A., Schindela, S., Kern, W., Haferlach, T. & Schnittger, S. (2013) The role of different genetic subtypes of CEBPA mutated AML. Leukemia, doi: 10.1038/leu.2013.273.
13. Gabert, J., Beillard, E., van der Velden, V.H., Bi, W., Grimwade, D., Pallisgaard, N., Barbany, G., Cazzaniga, G., Cayuela, J.M., Cave, H., Pane, F., Aerts, J.L., De Micheli, D., Thirion, X., Pradel, V., Gonzalez, M., Viehmann, S., Malec, M., Saglio, G. & van Dongen, J.J. (2003) Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a europe against cancer program. Leukemia, 17, 2318-2357.
14. Gorello, P., Cazzaniga, G., Alberti, F., Dell'Oro, M.G., Gottardi, E., Specchia, G., Roti, G., Rosati, R., Martelli, M.F., Diverio, D., Lo Coco, F., Biondi, A., Saglio, G., Mecucci, C. & Falini, B. (2006) Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia, 20, 1103-1108.
15. Grimwade, D., Vyas, P. & Freeman, S. (2010a) Assessment of minimal residual disease in acute myeloid leukemia. Current Opinion in Oncology, 22, 656-663.
16. Grimwade, D., Hills, R.K., Moorman, A.V., Walker, H., Chatters, S., Goldstone, A.H., Wheatley, K., Harrison, C.J., Burnett, A.K. & National Cancer Research Institute Adult Leukaemia Working Group. (2010b) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the united kingdom medical research council trials. Blood, 116, 354-365.
17. Harrison, C.J., Hills, R.K., Moorman, A.V., Grimwade, D.J., Hann, I., Webb, D.K., Wheatley, K., de Graaf, S.S., van den Berg, E., Burnett, A.K. & Gibson, B.E. (2010) Cytogenetics of childhood acute myeloid leukemia: United kingdom medical research council treatment trials AML 10 and 12. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28, 2674-2681.
18. Hokland, P. & Ommen, H.B. (2011) Towards individualized follow-up in adult acute myeloid leukemia in remission. Blood, 117, 2577-2584.
19. Jacobsohn, D.A., Tse, W.T., Chaleff, S., Rademaker, A., Duerst, R., Olszewski, M., Huang, W., Chou, P.M. & Kletzel, M. (2009) High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival. British Journal of Haematology, 146, 669-674.
20. Jansen, M.W., van der Velden, V.H. & van Dongen, J.J. (2005) Efficient and easy detection of MLL-AF4, MLL-AF9 and MLL-ENL fusion gene transcripts by multiplex real-time quantitative RT-PCR in TaqMan and LightCycler. Leukemia, 19, 2016-2018.
21. Juhl-Christensen, C., Ommen, H.B., Aggerholm, A., Lausen, B., Kjeldsen, E., Hasle, H. & Hokland, P. (2012) Genetic and epigenetic similarities and differences between childhood and adult AML. Pediatric Blood & Cancer, 58, 525-531.
22. Jurlander, J., Caligiuri, M.A., Ruutu, T., Baer, M.R., Strout, M.P., Oberkircher, A.R., Hoffmann, L., Ball, E.D., Frei-Lahr, D.A., Christiansen, N.P., Block, A.M., Knuutila, S., Herzig, G.P. & Bloomfield, C.D. (1996) Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood, 88, 2183-2191.
23. Kristensen, T., Moller, M.B., Friis, L., Bergmann, O.J. & Preiss, B. (2011) NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression. European Journal of Haematology, 87, 400-408.
24. Kronke, J., Schlenk, R.F., Jensen, K.O., Tschurtz, F., Corbacioglu, A., Gaidzik, V.I., Paschka, P., Onken, S., Eiwen, K., Habdank, M., Spath, D., Lubbert, M., Wattad, M., Kindler, T., Salih, H.R., Held, G., Nachbaur, D., von Lilienfeld-Toal, M., Germing, U., Haase, D., Mergenthaler, H.G., Krauter, J., Ganser, A., Gohring, G., Schlegelberger, B., Dohner, H. & Dohner, K. (2011) Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the german-austrian acute myeloid leukemia study group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29, 2709-2716.
25. Leung, W., Pui, C.H., Coustan-Smith, E., Yang, J., Pei, D., Gan, K., Srinivasan, A., Hartford, C., Triplett, B.M., Dallas, M., Pillai, A., Shook, D., Rubnitz, J.E., Sandlund, J.T., Jeha, S., Inaba, H., Ribeiro, R.C., Handgretinger, R., Laver, J.H. & Campana, D. (2012) Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood, 120, 468-472.
26. Marcucci, G., Strout, M.P., Bloomfield, C.D. & Caligiuri, M.A. (1998) Detection of unique ALL1 (MLL) fusion transcripts in normal human bone marrow and blood: distinct origin of normal versus leukemic ALL1 fusion transcripts. Cancer Research, 58, 790-793.
27. Ommen, H.B., Nyvold, C.G., Braendstrup, K., Andersen, B.L., Ommen, I.B., Hasle, H., Hokland, P. & Ostergaard, M. (2008) Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. British Journal of Haematology, 141, 782-791.
28. Ommen, H.B., Schnittger, S., Jovanovic, J.V., Ommen, I.B., Hasle, H., Ostergaard, M., Grimwade, D. & Hokland, P. (2010) Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood, 115, 198-205.
29. Ostergaard, M., Olesen, L.H., Hasle, H., Kjeldsen, E. & Hokland, P. (2004) WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. British Journal of Haematology, 125, 590-600.
30. Platzbecker, U., Wermke, M., Radke, J., Oelschlaegel, U., Seltmann, F., Kiani, A., Klut, I.M., Knoth, H., Rollig, C., Schetelig, J., Mohr, B., Graehlert, X., Ehninger, G., Bornhauser, M. & Thiede, C. (2012) Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia, 26, 381-389.
31. Schnittger, S., Wormann, B., Hiddemann, W. & Griesinger, F. (1998) Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors. Blood, 92, 1728-1734.
32. Schnittger, S., Schoch, C., Dugas, M., Kern, W., Staib, P., Wuchter, C., Loffler, H., Sauerland, C.M., Serve, H., Buchner, T., Haferlach, T. & Hiddemann, W. (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood, 100, 59-66.
33. Schnittger, S., Schoch, C., Kern, W., Mecucci, C., Tschulik, C., Martelli, M.F., Haferlach, T., Hiddemann, W. & Falini, B. (2005) Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood, 106, 3733-3739.
34. Schnittger, S., Kern, W., Tschulik, C., Weiss, T., Dicker, F., Falini, B., Haferlach, C. & Haferlach, T. (2009) Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood, 114, 2220-2231.
35. Schnittger, S., Haferlach, C., Ulke, M., Alpermann, T., Kern, W. & Haferlach, T. (2010) IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood, 116, 5486-5496.
36. Schnittger, S., Dicker, F., Kern, W., Wendland, N., Sundermann, J., Alpermann, T., Haferlach, C. & Haferlach, T. (2011) RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood, 117, 2348-2357.
37. Schnittger, S., Eder, C., Jeromin, S., Alpermann, T., Fasan, A., Grossmann, V., Kohlmann, A., Illig, T., Klopp, N., Wichmann, H.E., Kreuzer, K.A., Schmid, C., Staib, P., Peceny, R., Schmitz, N., Kern, W., Haferlach, C. & Haferlach, T. (2013) ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia, 27, 82-91.
38. Scholl, C., Breitinger, H., Schlenk, R.F., Dohner, H., Frohling, S., Dohner, K. & AML Study Group Ulm. (2003) Development of a real-time RT-PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia. Genes, Chromosomes & Cancer, 38, 274-280.
39. Silverman, L.R., Fenaux, P., Mufti, G.J., Santini, V., Hellstrom-Lindberg, E., Gattermann, N., Sanz, G., List, A.F., Gore, S.D. & Seymour, J.F. (2011) Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer, 117, 2697-2702.
40. Sockel, K., Wermke, M., Radke, J., Kiani, A., Schaich, M., Bornhauser, M., Ehninger, G., Thiede, C. & Platzbecker, U. (2011) Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse. Haematologica, 96, 1568-1570.
41. Steinbach, D., Schramm, A., Eggert, A., Onda, M., Dawczynski, K., Rump, A., Pastan, I., Wittig, S., Pfaffendorf, N., Voigt, A., Zintl, F. & Gruhn, B. (2006) Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. Clinical Cancer Research, 12, 2434-2441.
42. Stentoft, J., Hokland, P., Ostergaard, M., Hasle, H. & Nyvold, C.G. (2006) Minimal residual core binding factor AMLs by real time quantitative PCR-initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse. Leukemia Research, 30, 389-395.
43. Takatsuki, H., Yufu, Y., Tachikawa, Y. & Uike, N. (2002) Monitoring minimal residual disease in patients with MLL-AF6 fusion transcript-positive acute myeloid leukemia following allogeneic bone marrow transplantation. International Journal of Hematology, 75, 298-301.
44. Walter, R.B., Gooley, T.A., Wood, B.L., Milano, F., Fang, M., Sorror, M.L., Estey, E.H., Salter, A.I., Lansverk, E., Chien, J.W., Gopal, A.K., Appelbaum, F.R. & Pagel, J.M. (2011) Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29, 1190-1197.
45. Weisser, M., Kern, W., Schoch, C., Hiddemann, W., Haferlach, T. & Schnittger, S. (2005a) Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy. Haematologica, 90, 881-889.
46. Weisser, M., Kern, W., Rauhut, S., Schoch, C., Hiddemann, W., Haferlach, T. & Schnittger, S. (2005b) Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia, 19, 1416-1423.
47. Weisser, M., Haferlach, C., Hiddemann, W. & Schnittger, S. (2007) The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors. Leukemia, 21, 1177-1182.
48. Yin, J.A., O'Brien, M.A., Hills, R.K., Daly, S.B., Wheatley, K. & Burnett, A.K. (2012) Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the united kingdom MRC AML-15 trial. Blood, 120, 2826-2835.